HEC88473 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
HEC88473 is the only GLP-1 pairing on this site that is not with another gut hormone. It pairs GLP-1 with FGF21, a liver hormone, to hit appetite and liver fat through separate routes. So far it has only been tested as a single dose.
Evidence grade for HEC88473: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
1 effects reported, 1 unwanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
HEC88473 is an experimental shot that pairs two signals. One is GLP-1, the appetite signal Ozempic uses. The other is FGF21, a liver hormone that helps burn energy and clear liver fat. It has only been tested as a single dose. It is not approved anywhere.
What people take it for
- Weight loss.
- Fatty liver.
- Better blood sugar and blood fats.
What studies in people showed
There is one study in people. Healthy and obese Chinese adults got one shot, at rising doses. Blood sugar after a sugar drink fell at doses above about 5 mg. A hormone made by fat cells rose by up to 91 percent. Blood fats fell by up to 43 percent at the top dose. Nobody has tested whether it helps weight, liver fat or any disease. One shot in volunteers does not show that.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- In the single-dose study, most side effects were mild stomach upset.
Where these come from: The side effects and blood results are from the one study on this page. We have no forum reports for this one.
My bottom line
The idea is smart, because it does not just stack two appetite drugs. But one dose in volunteers is the very start. Come back when there is a real study.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 1 citation on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is HEC88473?
HEC88473 is the only GLP-1 pairing on this site that is not with another gut hormone. It pairs GLP-1 with FGF21, a liver hormone, to hit appetite and liver fat through separate routes. So far it has only been tested as a single dose.
Almost every two-in-one drug on this site pairs GLP-1 with GIP, glucagon or amylin. Those are all gut or pancreas hormones that work on related receptors. This one pairs GLP-1 with FGF21, which is a very different kind of signal.
FGF21 is a hormone the liver mostly releases when the body is under food stress. It works on fat and the brain to burn more energy, help the body handle blood sugar and lower liver fat. Drugs that copy FGF21 have mostly been made for fatty liver disease. This site covers three of them on their own pages.
Pairing the two means going after appetite and liver fat through routes that barely overlap. That is a better case for a combo than stacking two appetite signals. On this site, that approach has often run into shared side effects.
The only study so far gave people a single shot at rising doses. That is the start of a program, not a result.
How does HEC88473 work?
HEC88473 is one molecule that switches on two targets: the GLP-1 receptor and the FGF21 receptor. The GLP-1 side cuts how much you eat and helps control blood sugar, like other drugs of this type. FGF21 needs a helper protein called beta-klotho to work. Only some tissues have that helper, mainly fat, the liver and parts of the brain. So those are the places that respond. The FGF21 side makes the body burn more energy, handle blood sugar better and hold less fat in the liver. That is a very different job from cutting appetite. Beta-klotho is not the same gene as alpha-klotho, the protein linked to long life that has its own page here. People mix them up all the time.
What have studies in people found about HEC88473?
One first study in people, giving a single dose at rising amounts. No study of whether it helps anyone, and no repeat-dose data.
- One first study in people, with single shots at rising doses. It checked side effects, how the drug moved through the body, and what it did to blood tests.
- No larger study, no weight or liver fat result, and no repeat-dose data was found.
- The case for it rests on FGF21 drugs made for fatty liver disease, which have their own pages here.
What this does not tell you: A single-dose study is the earliest step in people there is. It tells you the drug can be given and how it behaves in the blood. It tells you nothing about whether it helps anyone. The interesting claim, that pairing GLP-1 with FGF21 does more than either one alone, has not been tested in people. Also worth knowing: drugs that copy FGF21 have a mixed record on big health outcomes, even though they reliably lower liver fat.
The state of the research
This drug earns a page for the pairing, not the data. The pairing is part of an argument this site makes across several pages.
The combo era in weight-loss drugs has mostly meant stacking appetite signals: GLP-1 with GIP, with glucagon, with amylin, with peptide YY. Where those have let people down, the reason has often been shared side effects, even when the drugs work in different ways. Nausea and a slow stomach pile up, and people hit the dose limit before the benefit arrives.
FGF21 is a truly different partner. It is a food stress signal that works on fat, liver and brain. It changes how much energy the body burns and how much fat the liver holds, rather than cutting appetite. So in theory, the combo could add benefit without adding the same side effects. Nobody knows if that holds up in a larger study, and a single-dose study is not proof that it will.
The evidence, in charts
Fig. 1a · how many people
1study in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 1 source here is a study in people.
- Study in people · done in people1100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2025.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- An engineered dual-activity biologic. No mass asserted; no source loaded states one.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not asserted. A single ascending dose study characterised pharmacokinetics; no half-life figure was resolved in the sources loaded.
No amino acid sequence is on file for HEC88473, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2025First-in-human study on tolerability, pharmacokinetics, and pharmacodynamics of single escalating doses of HEC88473, a novel dual GLP-1 and FGF21 receptor agonist
One single-dose study is all the proof in people for this drug. Healthy and obese Chinese adults got one shot, at doses from 0.5 mg up to 62.9 mg. Blood sugar after a sugar drink fell at doses above about 5 mg. A hormone made by fat cells rose by up to 91 percent, and blood fats fell by up to 43 percent at the top dose. Most side effects were mild stomach upset. One dose in volunteers proves nothing about treating a disease. The maker paid for it.
The entire human record for this compound: a first-in-human single ascending dose study reporting tolerability, pharmacokinetics and pharmacodynamics. Phase 1 single-dose work establishes that a molecule can be given to people and what it does to measurable parameters. It does not establish that it treats anything.
Common questions
Has HEC88473 been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. HEC88473 is the only GLP-1 pairing on this site that is not with another gut hormone. It pairs GLP-1 with FGF21, a liver hormone, to hit appetite and liver fat through separate routes. So far it has only been tested as a single dose.
What is the HEC88473 dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is HEC88473 FDA-approved?
Investigational, meaning still being tested. Only the first study in people has been done. Not approved anywhere.
What makes this different from tirzepatide?
Tirzepatide pairs GLP-1 with GIP, another gut hormone that works on a related receptor. This one pairs GLP-1 with FGF21, a liver hormone released under food stress, which works on fat, the liver and the brain through a different receptor. Their jobs barely overlap. That is a better case for a combo than stacking two appetite signals.
Does it work?
Nobody knows. The only study in people gave single shots at rising doses. That shows it can be given and how it behaves in the blood. There is no study of whether it helps anyone.
Is FGF21 related to klotho?
To beta-klotho, yes. That is the helper protein FGF21 needs to work, and it decides which tissues respond. It is a different gene from alpha-klotho, the protein linked to long life. People mix the two up a lot. This site keeps them apart on their own pages.